261 results about "Mucin" patented technology

The present invention provides a monoclonal anti-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological response to HMFG in nice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Le^a and Le(y) antibodies that bind to the Lewis antigens.

The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds of Formula II in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

wherein

• X is S, N, O or CR;
• Y is CRR′, O, NR₆, CRR′—CRR′ or CR═CR;
• Z is NR₆, O, S, CRR′ or CRR′—CRR′;
• R₁-R₃ are independently selected from the group consisting of H, C₁-C₈ alkyl, C₁-C₈ alkoxy, amino, hydroxy, halosubstituted alky and halo;
• R₄ is

or a pharmaceutically acceptable salt thereof.

A method for isolating, from a mixture, a virus having a surface protein with a binding site for sialic acid is provided. The method involves contacting the mixture with mucin which has been linked to a solid support and washing the solid support to remove material from the mixture is non-specifically bound to the mucin-linked support. Thereafter, the specifically bound virus (e.g., AAV4 or AAV5) may be removed in a further washing step utilizing a concentrated slat or solution with low pH. Also described are pharmaceutical kits containing solid supports linked to mucin for use in isolating virus having a surface protein with a binding site for sialic acid, or detecting the presence of the virus in a biological sample.

Strains of Lactobacillus that have been selected for their capability of reducing the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with good binding to the oral mucins and dental plaque, Administering the strains in a product such as food, reduces and treats dental caries. Preferred strains are Lactobacillus reuteri strain ATTC PTA-4965 or Lactobacillus reuteri strain ATTC PTA-4964.

A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.

Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

The extraction process of purple sweet potato anthocynidin and mucin includes the following steps: washing fresh or dry sweet potato, crushing, extracting in acid aqua, precipitation to eliminate starch and dregs, precipitating the supernatant with edible flocculant to obtain protein and polysaccharide, filtering, column adsorption of the filtrate, elution with acid methanol solution, decompressio concentration, and vacuum drying or spray drying to obtain product. Adopting acid solution extraction and flocculating mucinw ith flocculant to solve the filtering problem effectively, so that the present invention makes it possible to obtain anthocynidin and mucin simultaneously and has high anthocynidin purity and low production cost.

Cetyl pyridinium chloride and other amphiphilic substances may be mixed with flavorants or therapeutics in accompaniment with such as bulking agents or sweeteners in order to prolong their duration of action at the site of attachment, which is a mucin coated surface for the purpose of providing the consumer with a more efficacious product.It is the concept of delayed dispensing that is the invention, the product being dispensed is only an illustration of the best mode.

A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.

The invention provides fine dried noodles added with Chinese yam powder, pumpkin powder and millet flour, and a preparation method of the fine dried noodles. The fine dried noodles are made from the following raw materials in parts by weight: 75-85 parts of wheat flour, 10-15 parts of Chinese yam powder, 4-8 parts of pumpkin powder, 4-8 parts of millet flour, 2-3 parts of vital wheat gluten, 0.005-0.01 part of vitamin C, 26-32 parts of water, 2-3 parts of table salt and 0.08-0.1 part of CSL-SSL. In the fine dried noodles added with the Chinese yam powder, the pumpkin powder and the millet flour disclosed by the invention, the Chinese yam contains rich mucin, amylase, saponin, polyphenol oxide and the like, and has good health-care functions for human bodies; pumpkins contain pumpkin polysaccharide, carotenoid and pectin, and are a good vegetable extremely beneficial to the human bodies; millet contains excellent protein and rich mineral substances; and after food materials of the Chinese yam, the pumpkins and the millet are added, the nutrients of the fine dried noodles are more balanced.

The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).

The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.

Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's can further include one or more mucins, cytokines, or growth factors. Exemplary formulations include stem cells and SRMs derived from epithelial stem cells, corneal limbal stem cells, and fibroblasts. Other compositions and methods for formulation thereof are described.